Related Experiment Video
Updated: May 20, 2025
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
A Hypothesized Therapeutic Role of (Z)-Endoxifen in Duchenne Muscular Dystrophy (DMD)
H Lawrence Remmel1,2,3,4, Sandra S Hammer1, Laurence A Neff5,6
1Atossa Therapeutics, Inc., Seattle, WA, USA.
Abstract:
Duchenne Muscular Dystrophy (DMD) is an inherited, X-linked disorder that is progressive, debilitating, and ultimately fatal. The current therapeutic landscape offers no cures, but does include palliative treatments that delay disease progression, and there is progress on genetic therapies that have the promise to be curative. There is much room for new therapies, and foundational work with the estrogen receptor modulator tamoxifen suggests the potential of a unique spectrum of therapeutic benefit from endoxifen, a metabolite of tamoxifen. Here we describe the potential for this new DMD therapy in the context of the overall DMD therapeutic landscape.
Insights
Duchenne Muscular Dystrophy (DMD) is a fatal genetic disorder. Endoxifen, a tamoxifen metabolite, shows potential as a novel therapy to improve treatment outcomes for patients with this debilitating condition.
Area of Science:
- Biomedical Science
- Genetics
- Pharmacology
Background:
- Duchenne Muscular Dystrophy (DMD) is a progressive, inherited, X-linked disorder with no current cure.
- Existing treatments focus on palliative care and delaying disease progression.
- Emerging genetic therapies offer potential curative options for DMD.
Purpose of the Study:
- To explore the therapeutic potential of endoxifen, a metabolite of tamoxifen, for Duchenne Muscular Dystrophy.
- To evaluate endoxifen as a novel therapeutic agent within the current DMD treatment landscape.
Main Methods:
- Review of existing literature on tamoxifen and its metabolite, endoxifen.
- Analysis of the pharmacological properties of endoxifen relevant to DMD.
- Contextualization of endoxifen's potential within the existing DMD therapeutic landscape.
Main Results:
- Tamoxifen's metabolite, endoxifen, presents a unique therapeutic profile.
- Endoxifen's mechanism of action suggests potential benefits beyond current palliative DMD treatments.
Conclusions:
- Endoxifen represents a promising novel therapeutic candidate for Duchenne Muscular Dystrophy.
- Further research into endoxifen is warranted to establish its efficacy and safety in DMD patients.
